Change and Innovation

Current Priority Management Issues and Business Strategy

May 26, 2015



Masakazu Tokura President



Contents



Overview of FY2014 Performance and FY2015 Outlook



	FY2013	FY2014	Change
Net Sales	2,243.8	2,376.7	+132.9
Operating Income	100.8	127.3	+26.5
(Equity in Earnings of Affiliates)	12.0	23.9	+11.9
Ordinary Income	111.1	157.4	+46.3
Net Income	37.0	52.2	+15.2
ROE	6.5%	7.3%	
Naphtha Price	¥67,300/kl	¥63,500/kl	
Exchange Rate	¥100.17/\$	¥109.76/\$	

Current Priority Management Issues and Business Strategy

FY2014 Results: Operating Income by Sector

(Billions of ven)

	FY2013	FY2014	Change
Specialty Chemicals	120.2	118.3	-1.8
IT-related Chemicals	34.9	32.4	-2.5
Health & Crop Sciences	38.2	56.9	+18.7
Pharmaceuticals	47.1	29.0	-18.1
Bulk Chemicals	-5.9	20.8	+26.7
Basic Chemicals	-10.9	-0.4	+10.5
Petrochemicals & Plastics	4.9	21.2	+16.3
Others	-13.4	-11.8	+1.6
Total	100.8	127.3	+26.5

			(Billions of yen)
	FY2014	FY2015 (Forecast)	Change
Net Sales	2,376.7	2,250.0	-126.7
Operating Income	127.3	145.0	+17.7
(Equity in Earnings of Affiliates)	23.9	24.0	+0.1
Ordinary Income	157.4	160.0	+2.6
Net Income	52.2	80.0	+27.8
ROE	7.3%	10.0%	
Naphtha Price	¥63,500/kl	¥47,000/kl	
Exchange Rate	¥109.76/\$	¥115.00/\$	

Current Priority Management Issues and Business Strategy

(Bil	lions	of	yen)
				J /


	FY2014	FY2015 (Forecast)	Change
Specialty Chemicals	118.3	140.0	+21.7
Energy & Functional Materials	0.8	4.0	+3.2
IT-related Chemicals	32.4	41.0	+8.6
Health & Crop Sciences	56.1	63.0	+6.9
Pharmaceuticals	29.0	32.0	+3.0
Bulk Chemicals	20.8	17.0	-3.8
Petrochemicals & Plastics	20.8	17.0	-3.8
Others	-11.8	-12.0	-0.2
Total	127.3	145.0	+17.7

* After reorganization of the business sectors


Current Priority Management Issues and Business Strategy

Dividend Policy

We consider shareholder return as one of our priority management issues and have made it a policy to maintain stable dividend payment, giving due consideration to our business performance and a dividend payout ratio for each fiscal period, the level of retained earnings necessary for future growth, and other relevant factors.




Overview of Corporate Business Plan FY2013 to FY2015



Where We Have Been Heading

Change and Innovation



Current Priority Management Issues and Business Strategy

Progress on Business Restructuring: IT-related Chemicals and Health & Crop Sciences





Expanded small and medium-sized polarizing film production capacity

- Started mass production of next-generation polarizing films
- \checkmark
- Promoted a new polarizing film replacing a protection film



Increased on-cell touchscreen panel production capacity



Launched film touch sensors (UBT)

Expanded production capacity for aramid coated Li-ion secondary battery separators

Health & Crop Sciences Sector



Enhanced synergies from the alliance with Nufarm

- - Extended the period of the collaboration with Monsanto and expanded the collaboration into Brazil and Argentina



Expanded Flumioxazin herbicide production capacity

- Expanded seed treatment business
- Expanded post-harvest business
- Began operation of a new biorational plant



Acquired a rice seed business to enter "total solution provider" business for rice farming



Accelerated the development of new active ingredients for crop protection products

Progress on Business Restructuring: Pharmaceuticals and Bulk Chemicals

Pharmaceuticals Sectors



Additional indication approved in the U.S. for use of atypical antipsychotic LATUDA in treating bipolar I depression

Increased LATUDA sales in the U.S.

APTIOM launched in the U.S. as a treatment for epilepsy



Made progress on the development of BBI608 and BBI503, anticancer drugs targeting cancer stem cells



Made progress on the development of regenerative medicine and cell therapy

Restructured North American operations

Bulk Chemicals Sectors

Decided to close down liquid-phase process caprolactam plant



Closed down P-MMA plant in Japan



Closed down PO/SM plant



Amended the terms of transactions between Petro Rabigh and its founding shareholders



Maintain high-rate, stable operation of Rabigh Phase I Project facilities



Project finance agreement signed for Rabigh Phase II Project; facilities to come on stream in stages




Accepted orders for diesel particulate filters (DPFs)



Expanded production capacity for high-purity alumina and increased sales

Expanded S-SBR production capacity

Current Priority Management Issues and Business Strategy



	FY2015 (Target)	FY2015 (Forecast)	Change
Net Sales	2,400.0	2,250.0	-150.0
Operating Income	140.0	145.0	+5.0
(Equity in Earnings of Affiliates)	25.0	24.0	-1.0
Ordinary Income	150.0	160.0	+10.0
Net Income	90.0	80.0	-10.0
Naphtha Price	¥60,000/kl	¥47,000/kl	
Exchange Rate	¥80.00/\$	¥115.00/\$	

Current Priority Management Issues and Business Strategy


(Billions of yen)

	FY2015 (Target)	FY2015 (Forecast)	Change
Specialty Chemicals	129.0	140.0	+11.0
Energy & Functional Materials	15.0	4.0	-11.0
IT-related Chemicals	34.0	41.0	+7.0
Health & Crop Sciences	45.0	63.0	+18.0
Pharmaceuticals	35.0	32.0	-3.0
Bulk Chemicals	24.0	17.0	-7.0
Petrochemicals & Plastics	24.0	17.0	-7.0
Others	-13.0	-12.0	+1.0
Total	140.0	145.0	+5.0

* After reorganization of the business sectors

Current Priority Management Issues and Business Strategy

Change in operating income and its composition




Major increase in profitability of specialty chemicals

Current Priority Management Issues and Business Strategy

Current Status of Sumitomo Chemical

Change and Innovation



Enhance Financial Strength

Improve financial strength

Enhance financial strength

Improve asset efficiency (Improve CCC)

Target: Interest-bearing liability balance below ¥900 billion at the end of FY2015 Rigorously select investments

Secure greater strategic freedom to aggressively pursue growth opportunities

Current Priority Management Issues and Business Strategy

				(Billions of yen)
	FY2010-FY2012	FY2013-FY2015 (Target)	FY2013-FY2015 (Forecast)	FY2015 (Forecast)
Cash flows from operating activities	472.3	Around 540.0	715.2	260.0
Cash flows from investing activities	-445.7	*1 Below -400.0	-301.8	-110.0
Free cash flows	26.6	Over 200.0	413.4	150.0

(Note) *1: Including investment of 100 billion yen in Rabigh Phase II Project

*2: Including decreases in cash and cash equivalents


(Billions of yen)

	End of FY2012	End of FY2015 (Target)	End of FY2015 (Forecast)	End of FY 2014
Interest-bearing liabilities	1,060.6	*1 Below 900.0	850.0	980.2

(Note) *1: After spending 100 billion yen for investment in Rabigh Phase II Project

Interest-Bearing Liabilities and D/E Ratio

Change and Innovation




Progress on Major Projects

- IT-related Chemicals: Commercialization of Flexible Display Materials and Components
- Health & Crop Sciences: Expansion of Business Area
- Pharmaceuticals: Development of Regenerative Medicine
- Petrochemicals & Plastics: Expansion of Petro Rabigh
- Business Expansion in Niche Areas

IT-related Chemicals: Commercialization of Flexible Display Materials and Components


Change and Innovation



Current Priority Management Issues and Business Strategy


Health & Crop Sciences: Expansion of Business Area

Change and Innovation



Pharmaceuticals: Development of Regenerative Medicine

Change and Innovation



Development of regenerative medicine and cell therapy

	Partner	Region	Cell line		Timeli	ne to practio	al Implemen	tation		
	Fartner	Region	Cell line	2015	2016	2017	2018	2019	2020	
Chronic-stage cerebral infarction	SanBio	North America	Allogeneic mesenchymal stem cells		Ph2b				Approval (target)	
						Invoc	rigator-initiated	h3		
Age-related macular degeneration	Healios RIKEN	Japan	Allogeneic iPS cells	Clinical studie	s (autologous/a		igator-initiated		Approval (target)	
Parkinson's	Center for iPS Cell Research and	Global	Allogeneic					igator-initiated/ onsored clinica	I trials	
disease	Application (CiRA), Kyoto University			iPS cells		Clinical stud	lies (autologou	s)		
Retinitis pigmentosa	RIKEN	Global	Allogeneic iPS cells				Inv	vestigator-initia clinical trials	ted	
Spinal cord injury	Keio University Osaka National Hospital	Global	Allogeneic iPS cells				Clinic	al studies (allog	<mark>jeneic)</mark>	

Current Priority Management Issues and Business Strategy


1. Rabigh Phase II Project

(1) Outline of financing

	Financed	Remarks
Borrowing	5.2	Project financing
Capital, etc.	2.9	Bridge loans, etc.
Total	8.1	


Our planned investment: ¥100 billion (to be financed by free cash flows and borrowing)

(2) Progress of the project



2016 1H

(billion USD)



Current Priority Management Issues and Business Strategy

Business Expansion in Niche Areas


1. Sumitomo Joint Electric Power Co., Ltd.

Company Overview

Net sales: approx.¥48 billion^{*1} *1:FY2014 Established: 1919 Employees: approx.180^{*2} *2:End of FY2014

Business Overview

- Operation of power plants (3 thermal, 12 hydro, 1 biomass)
- Sale of power to Sumitomo Group companies, Shikoku Electric Power, Japan Electric Power eXchange (JEPX), etc.
- Planning to build new power plants to supply more power to customers outside the Sumitomo Group



2. Nihon Medi-Physics Co., Ltd.

Company Overview

Net sales: approx.¥32 billion^{*1} *1:FY2014 Established: 1973 Employees: approx. 800^{*2} *2:End of FY2014

Business Overview

- A leading nuclear medicine company in Japan (focus area: radiopharmaceuticals)
- Sale of SPECT diagnostic and PET diagnostic agents, radioactive seeds for cancer treatment, etc.
- Working to expand the application of PET diagnostic

New products (launched in 2014)

¹²³I-ioflupane (DaTscan intravenous injection)

 SPECT diagnostic agent for Parkinson's disease and Lewy body dementia

Development pipeline

¹⁸F-flutemetamol

• Under development as PET diagnostic agent for Alzheimer's disease

¹⁸F-fluciclovine

 Under development as PET diagnostic agent for brain tumors and prostate cancer

Current Priority Management Issues and Business Strategy

Business Expansion in Niche Areas


3. Valent BioSciences

Company Overview

Net sales: approx.USD280 million^{*1} Established: 2000 Employees: approx. 180^{*2} *1:FY2014 *2:End of FY2014

Business Overview

- A world leading biorational crop protection company
- Started a new plant in July 2014
- Acquired mycorrhizal fungi business in March 2015
- Seeking to develop synergies with chemical crop protection business




4. SCIOCS

Company Overview

Net sales: approx. ¥6 billion^{*1} Established: 2015 Employees: approx.160^{*2} *1:FY2014(forecast) *2:As of the end of April2015

Business Overview

- Sumitomo Chemical acquired compound semiconductor materials business from Hitachi Metals and established SCIOCS in April 2015
 - to expand share in gallium arsenide (GaAs) epiwafer market
 - to enter gallium nitride (GaN) substrate and epiwafer market (for use in power devices)
- Aiming to become a leading compound semiconductor materials company




Toward Sustained Growth

- Sumitomo Chemical: 100th Anniversary and Where We Are
- Priority Areas and Our Path Forward
- Strengthening Corporate Governance and Initiatives to Achieve Sustained Growth



Toward Sustained Growth

- Sumitomo Chemical: 100th Anniversary and Where We Are
- Priority Areas and Our Path Forward
- Strengthening Corporate Governance and Initiatives to Achieve Sustained Growth



Sumitomo Chemical's DNA


Sumitomo Values

The Sumitomo Family's "Business Principles" states that as we conduct business, we must always value trust and integrity and must closely watch the changing of the times, carefully weigh opportunities and risks, and seek long-term sustainable growth rather than chasing short-term gains.

At Sumitomo Chemical we adhere to the principle that our business must not only benefit our own interests but also society at large.

The origin of Sumitomo Chemical

Sumitomo Chemical's history dates back to 1913. The company got its start by producing fertilizer from harmful gas emitted in copper smelting operations. The business helped mitigate the environmental problem caused by the emissions, while also contributing to increasing agricultural crop production.



Change and Innovation

Sumitomo Chemical's 100 Years: Period of Expansion into New Business Areas

1915Start of business



1944

Sumitomo Fertilizer Manufacturing

Merger with Japan Dyestuff Manufacturing Company




Expanded into new business areas to respond to change in society and meet evolving customer needs

Current Priority Management Issues and Business Strategy

Sumitomo Chemical's 100 Years: Period of Expansion of Overseas Business and Globalization

Change and Innovation




Sumitomo Chemical's Globalization: Promotion of Globally Integrated Management Building competitive businesses globally by optimizing operations across national borders in view of technology, location, business partners, and human resource

Current Priority Management Issues and Business Strategy

Current Status of Sumitomo Chemical


Change and Innovation

Trends of Net Sales



Current Status of Sumitomo Chemical

Change and Innovation



Toward Sustained Growth

• Sumitomo Chemical: 100th Anniversary and Where We Are

• Priority Areas and Our Path Forward


• Strengthening Corporate Governance and Initiatives to Achieve Sustained Growth



Investment in Three Growth Areas

Change and Innovation





Current Priority Management Issues and Business Strategy

Life Sciences: Health & Crop Sciences

Change and Innovation

Trends

- Growing global population
- Increasing demand for food

Societal challenges and demands

Improvement of productivity of agriculture (limited availability of arable land and fresh water)

Solutions offered by the Sumitomo Chemical Group*

*including solutions under development

- Chemical and biorational crop protection solutions
- Seeds and seed treatment
- Post-harvest

- Crop stress management
- Total Solution Provider*
- * Support farmers' operations, from production to sale, by drawing on a wide range of agriculture-related supplies, technologies and know-how.

Current Priority Management Issues and Business Strategy

Change and Innovation

Life Sciences: Pharmaceuticals

Trends

Advances in healthcare technologies

Societal challenges and demands

Improvement of quality of life through new technologies, such as preventive diagnosis, personalized medicine, and regenerative medicine

Solutions offered by the Sumitomo Chemical Group*

*including solutions under development

- Regenerative medicine and cell therapy drugs
- Healthcare materials

- SPECT and PET diagnostic agents
- Drugs for the treatment of cancer and psychiatric and neurological disorders

Trends

- Advances in communication technology
- Advances in computer technologies
- Spread of IoT (Internet of Things)

Societal challenges and demands

Improvement of convenience and productivity by the IoT (Internet of Things)

Solutions offered by the Sumitomo Chemical Group*

*including solutions under development

- Display materials
- Organic EL

- Semiconductor Materials
- Aluminum target

- Printed electronics products
- Compound semiconductors

Environment and Energy

Change and Innovation

Trends

 Increasing global effort to develop a sustainable society

Societal challenges and demands

Development of products and processes that help reduce GHG emissions

Development of technologies for energy saving, creation and storage

Solutions offered by the Sumitomo Chemical Group*

*including solutions under development


- Energy carrier technology
- Compound semiconductors
- CO₂ separation materials
- Lighting materials
- Organic thin film solar cells

Battery materials


Solar cell parts and materials

Solutions In Three Growth Areas

Change and Innovation



Bulk Chemicals



Focus on establishing greater cost advantage and improving asset efficiency Aim to achieve ROI above cost of capital


Toward Sustained Growth

- Sumitomo Chemical: 100th Anniversary and Where We Are
- Priority Areas and Our Path Forward
- Strengthening Corporate Governance and Initiatives to Achieve Sustained Growth


Strengthening of Corporate Governance

Change and Innovation

Increased independent directors




To draw more on independent directors' broad expertise to further invigorate the board of directors



Initiatives for Enhancing Corporate Value


Change and Innovation



Current Priority Management Issues and Business Strategy

Toward the Next 100 Years

Change and Innovation



Creative Hybrid Chemistry



Cautionary Statement

Statements made in this document with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.